Trial Profile
A Phase 1, Randomised, Double-blind, Single-centre, Placebo-controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single S.C. Doses of RD01 (Pegerythropoietin) in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jan 2023
Price :
$35
*
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Anaemia
- Focus Adverse reactions; First in man
- Sponsors Sciprogen
- 13 Dec 2022 Results reporting safety, tolerability, and pharmacokinetics data of RD01 in healthy volunteers presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 13 Mar 2020 Status changed from recruiting to completed.
- 12 Sep 2018 New trial record